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To the Editor: As increased numbers of patients with congenital
heart disease (CHD) survive to adulthood, more women with
CHD are reaching reproductive age. Contraception and pregnancy
have now become important issues in this population; however,
both can be associated with increased risks in women with CHD
(1). Other issues, such as adverse fetal outcomes in these women
and transmission of CHD to offspring must be addressed. Current
guidelines for the care of adults with CHD recommend proactive
counseling regarding issues of contraception and pregnancy (2–5).
The objective of this study was to evaluate whether women with
CHD have adequate knowledge regarding risks of contraception
and pregnancy.
Women with CHD completed a questionnaire with items
pertaining to contraception history, perceived maternal and fetal
risks of pregnancy, and information they recalled receiving from
health care providers. An adult congenital cardiologist, blinded to
questionnaire responses, reviewed medical records in order to
determine maternal and fetal risks of pregnancy and whether there
were contraindications to specific modes of contraception. Con-
traindications to various forms of contraception were considered
based on recommendations and criteria from previously published
recommendations (1). Pregnancy risk was determined by considering
both global and lesion-specific risk factors (1–5). Pregnancy was
considered contraindicated in women with what is considered to be a
prohibitively high risk of maternal morbidity and mortality. Risks to
offspring were based on published transmission rates.
The final cohort was comprised of 116 women (mean age 31  9
years), of whom 62 (54%) had a college or university degree. The most
common cardiac diagnoses were tetralogy of Fallot (n 18), univen-
tricular heart/Fontan circulation (n  17), simple atrial or ventricular
septal defects or patent ductus arteriosis (n  16), or transposition of
the great arteries with an atrial switch operation (n  10).
Only 51% of women recalled receiving specific information
from a nurse or doctor about birth control. For 31 women (27%),
the use of combined oral contraceptives was felt to be contraindicated
(primary contraindications: Fontan physiology [n  16], Eisen-
menger/significant pulmonary hypertension/cyanotic heart disease
[n 9], and significant systemic ventricular dysfunction [n 2]); 14
of these women had used this method of birth control.
More than one-half (55%) of the participants had been preg-
nant at least once. Forty-three women (37%) reported that they
had never been informed that they were at increased risk for
maternal cardiac complications during pregnancy (Table 1). Of 80
women considered to be at intermediate or high risk for pregnancy
complications, 27 (34%) did not recall receiving this information.
Women with post-secondary degrees were more likely to recognize
they were at increased risk (79% vs. 55%, p  0.01). Forty-one
women (37%) did not think their children would be at increased
risk of having heart problems.
Based on medical record review, 18 women (16%) had contra-
indications to pregnancy: 8 had Eisenmenger syndrome/significant
pulmonary hypertension/cyanotic heart disease; 6 were felt to
require surgery before undergoing a pregnancy; 2 had Fontan
circulation with systemic ventricular dysfunction or poor functional
class; 1 had uncontrolled hypertension in the setting of coarctation
of the aorta; and 1 had a mechanical valve with systemic ventricular
dysfunction. Of 18 women who would currently be advised to
avoid pregnancy, only 9 recalled having received this advice. Of 98
women for whom pregnancy would not be contraindicated, 18 said
that a doctor or nurse had previously advised them to avoid
pregnancy (Table 1).
In this study, we found that many women with CHD have a
significant lack of accurate contraception and pregnancy knowl-
edge. It is not evident why women have not acquired this
knowledge. Are physicians not providing the information, are they
providing inaccurate information, or are women not retaining the
information? Beginning in adolescence, women with CHD should
be provided with accurate information about contraception and the
Current Versus Recalled Advice Regarding Pregnancy Risk
Table 1 Current Versus Recalled Advice Regarding Pregnancy Risk
Physician-Rated Current Risk of
Maternal Cardiac Complications
Low Risk
Intermediate or
High Risk Total
Patient recalls being informed of increased
risk of maternal complications
No 16 27 43 (37%)
Yes 20 53 73 (63%)
Physician-Rated Current
Contraindication to Pregnancy
No Yes
Patient recalls being told to postpone or
avoid pregnancy
No 80 9 89 (77%)
Yes 18 9 27 (23%)
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implications of heart disease on pregnancy. Appropriate advice and
information likely fluctuates in accordance with cardiac or hemo-
dynamic changes across time. There are several models to address
this issue, including a collaborative approach between adult CHD
and contraception clinics and the incorporation of contraception
and pregnancy counseling by advanced practice nurses within
CHD clinics. Responsible health care professionals working with
women with CHD will provide information and guidelines, but
final decision-making lies with patients and must be respected,
even if it differs from medical advice.
This study has limitations. Because guidelines relating to preg-
nancy and contraception in women with CHD are not evidence-
based, it is important that physicians weigh the risks and benefits for
each individual. This study investigated patient-recalled information
versus physician-provided information, as no data were available
regarding the exact nature of the advice provided to women.
In conclusion, many women with CHD lack adequate knowl-
edge regarding contraception and pregnancy risks. Accurate and
continuing education should be a priority in order to ensure that
both patients and healthcare professionals have access to the most
current information.
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Letters to the Editor
Editor’s Note
Our usual policy at JACC is to limit Letters to the Editor
and their replies to a total of 400 words. However, we have
recently encountered 2 letters which considerably exceeded
this limit and provoked replies of similar length. Both
interchanges dealt with issues of substantial current interest
and importance: the role of intervention following infarc-
tion, particularly for patients with total coronary occlusion,
and the role of percutaneous intervention versus surgery for
unprotected left main coronary stenosis. Therefore, we have
decided to make an exception and to publish the letters and
replies as submitted. We believe that a thorough airing of
these topics more than justifies this exception.
A Meta-Analysis
That Misses the Mark
In the February 7, 2008, issue of the Journal, Abbate et al. (1)
present a meta-analysis with a stated goal of including randomized
controlled trials of late percutaneous coronary intervention (PCI)
of the infarct-related artery (IRA) in stable patients 12 h after
onset of myocardial infarction (MI) (1). A fundamental principle
of meta-analysis is inclusion of all studies that meet stated
eligibility criteria with common end point definitions. The meta-
analysis should address a relevant clinical question. Whether totally
occluded IRAs should be opened in stable patients late after MI
onset (the late open artery hypothesis) is an important question,
and the authors introduce this concept early in the report.
However, of the 10 studies included in the Abbate et al. (1)
analysis, only 6 set out specifically to test the late opening of
occluded IRA hypothesis, while 4 studies (TOPS [Treatment of
Post-Thrombolytic Stenosis], BRAVE 2 [Beyond 12 Hours
Reperfusion Alternative Evaluation], SWISSI II [Swiss Interven-
tional Study on Silent Ischemia Type II], and ALKK [Arbeitsge-
meinschaft Leitende Kardiologische Krankenhausärzte]) were ex-
amining whether or not to perform PCI in patients beyond the
acute phase of MI when the IRA was often patent after fibrinolytic
therapy or patients were randomized in order to evaluate a global
invasive versus selective, ischemia-driven, invasive care strategy
(the BRAVE 2 trial). For example, the BRAVE 2 trial is not
applicable to address the late open artery hypothesis, since one-half
of those enrolled in the BRAVE 2 trial did not have initial
angiography, one-half of those with angiograms had open arteries,
and PCI, coronary artery bypass grafting, or no procedure was
performed in the invasive group. The SWISSI II trial selectively
enrolled patients with silent ischemia and 1- to 2-vessel disease,
with no information on the status of the IRA provided, up to 3
months after ST-segment elevation myocardial infarction
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